Trial | NCT02273895  Report issue

Title

The Use of EEG in Alzheimer's Disease, With and Without Scopolamine - A Pilot Study
Development of a Diagnostic Tool for Alzheimer's Disease

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Indication/Condition

    AD

  • Study Participants

    29
The objective of this study is to compare the electroencephalography (EEG) responses of three distinct groups of individuals to scopolamine: 1) a group of Alzheimer Dementia (AD) patients, 2) a group of individuals suffering from Mild Cognitive Impairment (MCI) and 3) a group of controls. The main purpose of this comparison is to discover ways to use these responses to distinguish between the group of AD patients and controls in order to develop a diagnostic tool for AD. The purpose of including the MCI group is to investigate whether this diagnostic tool can predict which member of the MCI group will develop AD later in life.
Study Started
Apr 30
2004
Primary Completion
Oct 31
2004
Study Completion
Jan 31
2010
Last Update
Oct 24
2014
Estimate

Drug Scopolamine

0.3 mg/mL, intravenously, once

  • Other names: Scopolamine hydrobromide

Control Active Comparator

Scopolamine

MCI Active Comparator

Scopolamine

AD Active Comparator

Scopolamine

Criteria 

Inclusion Criteria:

Healthy subjects:

Between 60-80 years of age.
Volunteers will have to be in good general health as determined by standard physical examination.
Normal Electrocardiograph (ECG)

MCI subjects:

Diagnosed with MCI at the Memory Clinic at the Landspitali University Hospital using F 06,7 according to International Classification of Diseases (ICD) - 10.
Between 60-80 years of age.
Subjects need to score between 2 and 3 on the Global Deterioration Scale (GDS).
Normal ECG

Alzheimer's patients:

Diagnosed with AD according to ICD - 10 in Follow up at the Memory Clinic at the Landspitali University Hospital.
Between 60-80 years of age.
Subjects need to score between 3-5 on the GDS.
Normal ECG
Treated with Reminyl® for the Alzheimer disease.

Exclusion Criteria:

Smoking or any other use of tobacco.
Taking neuroleptics or benzodiazepines (allowed to take oxazepam ad vesp).
Neurological-, cardiovascular-, gastrointestinal- or genitourinary disorders of medical importance.
Glaucoma or history of possibly raised intraocular pressure.
Impaired liver- or kidney function.
Hypersensitivity to Scopolamine or any component in the formulation.
Any indication of drug, alcohol or medicine abuse.
Participation in another investigational study at the same time.
No Results Posted